Description
Tiloram Pharmacodynamics
Low-molecular synthetic inducer of interferon, stimulating the formation of interferon alpha, beta and gamma in the body. The main producers of interferon in response to tiloron administration are intestinal epithelial cells, hepatocytes, T-lymphocytes, neutrophils and granulocytes.
After oral administration the maximum production of interferon is determined in the sequence intestine – liver – blood in 4-24 hours.
Tiloron has immunomodulatory and antiviral effects. In human leukocytes it induces synthesis of interferon.
It stimulates bone marrow stem cells, and, depending on the dose, enhances antibody production, reduces the degree of immunosuppression, restores the ratio of T-suppressors and T-helpers.
Effective against a variety of viral infections, including influenza viruses, other acute respiratory viral infections, hepatitis viruses and herpesviruses. The mechanism of antiviral action is associated with inhibition of translation of virus-specific proteins in infected cells, resulting in suppression of virus reproduction.
Indications
In adults:
– Treatment of influenza and other acute respiratory infections;
– Treatment of herpetic infections. Prevention of influenza and other acute respiratory viral infections.
Contraindications
– Hypersensitivity to tiloron and other components of the drug.
– Pregnancy and lactation.
– children under 18 years of age
– hereditary lactose intolerance, lactase deficiency, glucose-galactose malabsorption.
Administration during pregnancy and lactation
Safety of use during pregnancy and lactation has not been studied.
The drug is contraindicated during pregnancy. If it is necessary to prescribe the drug during lactation, breast feeding should be stopped.
Dosage and administration
- Tiloron is taken orally, after a meal.
- For the treatment of flu and other acute respiratory viral infections – 125 mg per day for the first 2 days of treatment, then 125 mg every 48 hours. For a course of 750 mg.
- For the prevention of flu and other acute respiratory viral infections – 125 mg once a week for 6 weeks. For a course of 750 mg.
- For the treatment of herpetic infection – the first two days with 125 mg, then 48 hours later with 125 mg. The course dose is 1.25-2.5 g.
- When treating influenza and other acute respiratory infections, if symptoms persist for more than 4 days, consult a physician.
